TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sepsis Trial of Early Physical Therapy Outside the ICU

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Any English-speaking patient over the age of 18 who is currently admitted to a general care floor under the care of the Medicine Faculty Hospitalist Service at the University of Michigan Health System and has severe sepsis is eligible to take part in this study.~Exclusion Criteria:~* Subjects must be deemed by the study team to give informed consent by being able to state the basic purpose of the study. Consent by a legally authorized representative (LAR) will not be sought.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Additional physical therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gastric Restriction Using the EndoSurgical Operating System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has met diabetic lab testing and all pre-procedural qualifications as delineated below.~* Patient is \>/= 20 yrs. of age and \</= 60 yrs. of age~* Patient has a BMI of \>/=30 and \< 40~* Patient has history of obesity for \>/= 2 yrs.~* Patient has had not significant weight change (\<5% of total body weight) in last 6 months.~* Patient is a reasonable candidate for general anesthesia~* Patient agrees not to have any additional weight loss surgery or liposuction for 2 yrs. following procedure.~Exclusion Criteria:~* Patient is not able and willing to return for all follow-up evaluations, tests and nutritional counseling.~* Patient is not able to provide written informed consent~* Patient has history or present use of insulin or insulin derivatives for treatment of diabetes.~* Patient has diabetes secondary to a specific disease.~* Patient has history of inflammatory disease of GI tract~* Patient has diabetic retinopathy~* Patient has chronic pancreatic disease~* Patient ahs active peptic ulcer~* Patient has portal hypertension~* Patient has esophageal varices~* Patient has significant esophageal disease~* Patient has a history of any significant abdominal surgery~* Patient has a history of any bariatric or GERD surgical procedures~* Patient has a hiatal hernia \> 2cm.~* Patient has esophageal stricture or other anatomy and/or condition that could preclude passage of endolumenal instruments~* Patient is of childbearing age and not practicing effective birth control method, pregnant or lactating.~* Patient has had a MI or CVA in last year, or has unstable cardiovascular disease.~* Patient has cancer or life expectancy of \< 2 yrs.~* Patient currently uses or has used over the counter or prescription weight loss drugs in last month or intends to use during follow-up Registry period.~* Patient has quit smoking within last 6 months or plans to quit smoking in the next year.~* Patient has a history of durg or alcohol abuse~* Patient has uncontrolled depression, psychosis, or eating disorder.~* Patient is non-ambulatory or has significant impairment of mobility.~* Patient has known hormonal or genetic cause for obesity.~* Patient is participating in another Registry and/or Study that could adversely affect this Registry.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- EOS (Type: EXPERIMENTAL): Collecting data on the use of the EOS for gastric tissue approximation during primary gastric restrictive procedures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose PG102 in Patients With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Arthritis that meets Classification of Psoriatic Arthritis (CASPAR) criteria~* Plaque psoriasis for at least 6 months prior to study enrollment~Exclusion Criteria:~* Clinically significant psoriasis flare~* Unstable doses of pain relief medication~* Treatment with systemic corticosteroids other than prednisone ≤ 10 mg/day or equivalent~* Treatment with any biologic therapy~* Treatment with immunosuppressive agents or disease modifying anti-rheumatic drugs (DMARDs) other than methotrexate~* Treatment with lithium, any anti-malarial, chlorambucil, cyclophosphamide or therapies for psoriasis other than low potency topical corticosteroids on intertriginous and groin areas, tar or salicylate preparations on the scalp, and emollients and moisturisers~* Family history of multiple thrombotic events or a personal history of any venous or arterial thrombotic event~* Clinically significant result for anti-cardiolipin, Activated protein C resistance test, Protein C, Free Protein S, Antithrombin III, Factor V Leiden, Prothrombin variant, Homocysteine, Lupus anticoagulant, Prothrombin time, Activated partial thromboplastin time, Fibrinogen, Thrombin time, Factors IX and XI~* Currently smoking ≥ 10 cigarettes per day or equivalent~* Active tuberculosis or other infection~* Current or previous malignancies~* Clinically significant abnormality on physical examination, laboratory testing, vital signs or 12-lead electrocardiogram

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PG102 0.3 mg/kg (Type: EXPERIMENTAL): Lowest dose PG102
- PG102 1 mg/kg (Type: EXPERIMENTAL): Second dose PG102
- Placebo (phosphate-buffered saline) (Type: PLACEBO_COMPARATOR): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy persons aged ≥ 18, and able to give informed consent~* Patient is admitted to hospital~* Primary reason for hospital admission is clinical suspicion of a new episode of ARI~* Onset of the following symptoms within the last 7 days: i. Sudden onset of self-reported fever OR temperature of ≥ 38°C at presentation AND ii. At least one respiratory symptom (cough, sore throat, runny or congested nose, dyspnoea) AND iii. At least one systemic symptom (headache, muscle ache, sweats or chills or tiredness).~Exclusion Criteria:~* Patient lacks capacity to provide informed consent~* Patient has been transferred from another hospital~* Patient has been previously enrolled in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women with newly diagnosed DCIS. Women will be considered to be in menopause if they fall into one of the following groups:~  * Age \> 60~ * Age \> 45 with amenorrhea \> 1 year with intact uterus~ * Status post bilateral oophorectomies~ * FSH/estradiol levels in postmenopausal range for the institution~* DCIS must have been diagnosed with a minimally invasive biopsy technique, such as a vacuum-assisted large core tool (Mammotome) or an equivalent method.~* There must be available tissue from the diagnostic biopsy to perform molecular markers.~* Baseline mammogram within 8 weeks of study entry.~* Serum creatinine less than or equal to 2.0 mg/dl.~* Total bilirubin less than or equal to 2.0 upper limit of normal (ULN), transaminases (SGOT and/or SGPT) and alkaline phosphatase may be up to 2.5 x institutional upper limit of normal (ULN), AGC greater than or equal to 1500, platelets greater than or equal to 100,000, Hemoglobin greater than or equal to 8.0 g/dl~* Peripheral neuropathy grade 0-1.~* No prior therapy for DCIS.~* SWOG performance status of less than or equal to 1~* All patients must provide informed written consent~Exclusion Criteria:~* Prior hormonal therapy (antiestrogens, estrogen, SERM's, progestins, or aromatase inhibitors) within 6 months of study entry.~* Underlying medical, psychiatric or social conditions that would preclude patient from receiving treatment.~* History of DVT or Pulmonary Embolism

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): None
- 2 (Type: ACTIVE_COMPARATOR): Tamoxifen 20 mg
- 3 (Type: ACTIVE_COMPARATOR): Fulvestrant 250mg
- 4 (Type: ACTIVE_COMPARATOR): Fulvestrant 500mg IM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Resistant Starch in COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* greater than 18 years of age~* COVID-positive status~* Being monitored in an outpatient setting at one of our study sites:~* Yale New Haven Hospital (YNHH)~* University of Michigan~* University of Minnesota~Exclusion Criteria:~* inflammatory bowel disease~* history of gastric bypass surgery~* active Clostridium difficile infection~* active participation in another COVID-19 interventional trial~* any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient or raise concern that the patient would not comply with the protocol procedures.~* Reported allergy to starch~* Difficulty swallowing in order to prevent any aspiration risk~* Currently taking any IL-6 inhibitors such as Tocilizumab for any disease condition

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Subjects will receive a dietary supplement containing resistant starch and be instructed to take 2 tablespoons (\~20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days prior to increasing to 2 tablespoons twice daily.
- Control (Type: PLACEBO_COMPARATOR): Subjects will receive a placebo starch, consisting of non resistant starch and be instructed to take 2 tablespoons (\~ 20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of metastatic breast cancer that has progressed on or failed at least one salvage chemotherapy regimen for metastatic disease and that meets the following disease specific related criteria:~  * Measureable metastatic disease per Response Evaluation Criteria In Solid Tumor (RECIST) - bone only not eligible.~ * Disease progression while receiving prior therapy with a hormonal agent (if estrogen/progesterone receptor-positive) and/or trastuzumab (Herceptin®) (if HER2-neu positive)~ * Brain metastases allowed provided they are stable for ≥ 3 months after prior treatment~* Related HLA-haploidentical natural killer cell donor available (by ≥ class I serologic typing)~* Male or female~* Performance status 50-100%~* Platelet count ≥ 80,000/mm³ (unsupported by transfusions)~* Hemoglobin ≥ 9 g/dL (unsupported by transfusions)~* Absolute neutrophil count ≥ 1,000/mm³ (unsupported by sargramostim \[GM-CSF\] or filgrastim \[G-CSF\])~* Creatinine ≤ 2.0 mg/dL~* Liver function tests \< 5 times normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* LVEF \> 40%\*~* Pulmonary function \> 50%\* (DLCO corrected AND FEV_1)~* No active infection (i.e., afebrile, off antibiotics, and no uninvestigated radiologic lesions)~Exclusion Criteria:~* At least 3 days since prior prednisone or other immunosuppressive medications~* No other concurrent therapy for cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Treated Patients (Type: EXPERIMENTAL): All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Soft tissue sarcoma (including high grade or low grade soft tissue sarcoma、osteogenic sarcoma and the following 4 recurrent benign tumors which may have aggressive clinical course after initial surgical treatment : lymphangioleiomyomatosis、angiomyolipoma、giant cell tumor、phylloid tumor) that are refractory to at least first line full course of standard chemotherapy, relapsed after standard chemotherapy, or who have no standard therapy available and refused chemotherapy~* Patients must be \>/= 21 years.~* Patients must be \>/= 4 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. Patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol. For biologic/targeted agents patients must be \>/= 5 half-lives or \>/= 3 weeks form the last dose (whichever comes first).~* Eastern Cooperative Oncology Group(ECOG) performance status \</= 2~* Patients must have certain organ and marrow function resave defined as: White blood cell(WBC_ \>/= 3,000/mL;platelets \>/=100,000/mL; creatinine \</= 2 X Upper Limit of Normal (ULN); total bilirubin \</= 2.0; Alanine Aminotransferase(ALT;SGPT) \</= 5 X ULN; Exception for patients with liver metastasis: total bilirubin \</= 3 x ULN; ALT(SGPT) \</= 8 X ULN;cholesterol \</= 350 mg/dL; triglycerides \</= 400 mg/dL (sirolimus and hydroxychloroquine only).~* Patients must be able to understand and be willing to sign a written informed consent document.~Exclusion Criteria:~* Uncontrolled intercurrent illness, including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support.~* Pregnant or lactating women.~* History of hypersensitivity to sirolimus.~* History of hypersensitivity to hydroxychloroquine~* Patients unwilling or unable to sign informed consent document.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus and hydroxychloroquine (Type: EXPERIMENTAL): Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally once daily(QD) for 2 cycles . Each treatment cycle is 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are eligible for Erbitux treatment according to the indication in the national label of Erbitux (i.e. in EGFR expressing, KRAS wild-type metastatic colorectal adenocarcinoma).~* Subjects who have failed oxaliplatin and irinotecan-based therapy and who are intolerant to irinotecan in mCRC.~* Subjects who have signed the informed consent form~Exclusion Criteria:~* Subjects who do not fall under the approved indications according to the national label of Erbitux.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (Trial-related activities are any procedures that would not have been performed during normal management of the subject)~2. Completion of study HGT-MLD-048 (NCT00633139)~3. The subject and his/her guardian(s) must have the ability to comply with the protocol~Exclusion Criteria:~1. Spasticity so severe to inhibit transportation~2. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition that, in the opinion of the Investigator, would preclude participation in the trial~3. Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- HGT-1111 100 U/kg (Type: EXPERIMENTAL): None
- HGT-1111 200 U/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hepatocellular carcinoma~  * Not amenable to surgical resection or immediate liver transplantation~    * Destaging of tumor prior to surgical resection or transplantation allowed~* Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) ≥ 10 mm by contrasted CT scan~  * No equivocal, nonmeasurable, or nonevaluable liver cancer~* No more than 75% replacement of normal liver by tumor~* Cancer of the Liver Italian Program (CLIP) stage 1-3 disease~* No extra-hepatic metastases as determined by CT scan or MRI~Exclusion Criteria:~* Life expectancy ≥ 3 months~* Karnofsky performance status 50-100%~* Creatinine ≤ 1.5 mg/dL~* Bilirubin ≤ 2.0 mg/dL~* Albumin ≥ 3 g/dL~* Granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 65,000/mm³~* INR ≤ 1.4~* Hemoglobin \> 9 g/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* No nonmalignant disease that would render the patient ineligible for treatment according to this protocol~* No hepatic arterial anatomy that would prevent the administration of study drug into the liver~* Less than 20% arteriovenous lung shunting on a technetium 99m-labeled macroaggregated albumin nuclear scan~* No other malignancy within the past 5 years except for cured basal cell carcinoma of the skin or cured carcinoma in situ of the uterine cervix~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 90 days since prior surgery, chemotherapy, or locally ablative technique for the liver cancer~* More than 4 weeks since prior and no other concurrent investigational drug or agent/procedure (i.e., participation in another trial)~* No prior radiotherapy to the upper abdomen that included the liver in the treatment field~* No capecitabine within 8 weeks before or after study treatment~* No other anticancer treatment (except surgical resection) for liver cancer during and for 3 months after completion of study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- SIR-SPHERES (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues